Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fibrogen Inc CS 409 ILLINOIS STREET SAN FRANCISCO CA 94158 USA

P: 415-978-1200 F: +63 26314691

Description:

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 3,866,291
Shares Outstanding, K 90,355
Annual Sales, $ 256,580 K
Annual Net Income, $ -76,970 K
Last Quarter Sales, $ 42,890 K
Last Quarter Net Income, $ -85,310 K
60-Month Beta 1.63
% of Insider Shareholders 3.39%
% of Institutional Shareholders 73.51%
Float, K 87,292
% Float 96.61%

Growth:

1-Year Return 12.40%
3-Year Return -20.46%
5-Year Return 90.18%
5-Year Revenue Growth 86.47%
5-Year Earnings Growth 71.92%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.95 on 08/06/20
Next Earnings Date 11/09/20
Earnings Per Share ttm -3.53
EPS Growth vs. Prev Qtr -6.74%
EPS Growth vs. Prev Year -175.40%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

FGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -45.47
Price/Earnings to Growth N/A
Return-on-Equity % -60.97%
Return-on-Assets % -36.79%
Profit Margin % -30.00
Net Margin % N/A
Debt/Equity 0.07
Price/Sales 15.49
Price/Cash Flow N/A
Price/Book 9.41
Book Value/Share 4.66
Interest Coverage -25.61
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar